Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Ambu    AMBU B   DK0060946788

AMBU

(AMBU B)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Ambu : Medical device maker Ambu's shares dive after new CEO cuts outlook

share with twitter share with LinkedIn share with facebook
share via e-mail
0
06/18/2019 | 03:50am EDT

COPENHAGEN (Reuters) - Shares in Danish medical device maker Ambu plunged 18% in early trade on Tuesday after its new chief executive announced cuts to the company's growth prospects for this year and next.

The reduction in targets is Chief Executive Officer Juan-José Gonzalez's first big announcement after the former Johnson & Johnson executive took over from Lars Marcher last month.

During more than a decade at the helm, Marcher presided over a roughly 5,000 percent rise in the company's shares as he led the company's successful expansion of diagnostic and life-support devices for hospitals, focusing on products such as single-use endoscopes.

Ambu's shares have fallen more than 40% since Marcher's unexpected exit when the company said it wanted a CEO with a strong international profile as it sought to expand globally.

On Tuesday, Ambu said that its lower growth outlook for the current fiscal year was partly due to discontinuation of one of its colonoscopes, called SC210, after it disappointed in tests in a U.S. hospital.

For the 2018/2019 financial year ending in September, it said it now expects organic revenue growth of 14-15% down from a previous guidance of 15-16% and an EBIT-margin before special items of around 22% compared to a previously stated 22-24%.

It also said it would invest 225 million Danish crowns (£27 million) in sales and marketing and more than double its global sales force and launch a number of new products.

"We will fulfil our aspiration to become one of the major European medical devices companies," Gonzalez, an American, said.

In the 2019-2020 financial year Ambu now sees organic revenue growth of 16-19%, down from a previously forecasted 18-23%, and an EBIT margin of at least 20% compared to a previous estimate of 26-28%.

Free cash flows in 2019-2020 are now estimated to be around 9% of revenue compared to previously 18% of revenue.

(Reporting by Stine Jacobsen; Editing by Susan Fenton)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on AMBU
06/18AMBU : Medical device maker Ambu's shares dive after new CEO cuts outlook
RE
06/17AMBU A/S : Review of the Big Five 2020 Strategy
AQ
05/20AMBU A/S : Cook Medical and Ambu announce collaboration to address endoscope-rel..
AQ
05/18AMBU A/S : Cook Medical and Ambu announce collaboration to address endoscope-rel..
AQ
05/10AMBU A/S : Ambu appoints new CEO
AQ
05/09AMBU A/S : Updated Articles of Association May 2019
AQ
05/09AMBU A/S : Capital increase in connection with exercise of warrants issued
AQ
05/01AMBU A/S : Interim report for Q2 2018/19 and for the period 1 October 2018 - 31 ..
AQ
04/03INVESTORS : Ambu has best medtech CEO in Europe
PU
03/18NEW STUDY : Reusable Bronchoscopes cost more than Sterile Single-use Bronchoscop..
PU
More news
Financials (DKK)
Sales 2019 3 091 M
EBIT 2019 675 M
Net income 2019 429 M
Debt 2019 1 061 M
Yield 2019 0,50%
P/E ratio 2019 59,4x
P/E ratio 2020 48,0x
EV / Sales2019 8,35x
EV / Sales2020 7,13x
Capitalization 24 736 M
Chart AMBU
Duration : Period :
Ambu Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AMBU
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 6
Average target price 122,40  DKK
Last Close Price 101,00  DKK
Spread / Highest target 83,2%
Spread / Average Target 21,2%
Spread / Lowest Target -22,8%
EPS Revisions
Managers
NameTitle
Lars Marcher President & Chief Executive Officer
Jens Bager Chairman
Bjarne Nørgaard Sørensen Executive Vice President-Global Operations
Michael Højgaard Chief Financial Officer & Executive Vice President
Mikael Worning Vice Chairman
Sector and Competitors
1st jan.Capitalization (M$)
AMBU-35.50%3 718
MEDTRONIC PLC10.82%135 189
BAXTER INTERNATIONAL INC.26.25%42 395
HOYA CORPORATION25.75%28 471
ZIMMER BIOMET HOLDINGS19.02%25 282
ALIGN TECHNOLOGY34.27%22 498